Colonna Sarah, Curtin Karen, Johnson Eric, Kohlmann Wendy, Wright Jennifer, Kirchhoff Anne, Tavtigian Sean, Schiffman Joshua
Huntsman Cancer Institute, The University of Utah, USA.
Department of Internal Medicine, The University of Utah, USA.
Int J Cancer Clin Res. 2019;6(1). doi: 10.23937/2378-3419/1410107. Epub 2019 Feb 25.
Advances in treatments for Hodgkin Lymphoma (HL) have significantly increased survival of childhood and adult patients; however, the leading cause of death in HL survivors is due to secondary malignancy following HL treatment [1,2]. Among women treated for HL, breast cancer (BC) is the most common secondary malignancy [3]. We explored if an association exists between HL and BC exists within families.
Utilizing the Utah Population Database and the Utah Cancer Registry, we identified 988 women with HL, and no history of BC prior to HL, diagnosed in Utah from 1966-2014. We examined if women with HL were at greater risk of developing BC based on the presence or absence of family history of BC. We also examined the familial recurrence risk of BC among female FDRs of women with HL and BC using Cox regression methods.
Among 988 female HL patients, 42 (4.3%) were diagnosed with subsequent BC while among 9,876 matched controls, 280 controls (2.8%) were diagnosed with BC from 1966-2014 ( < 0.05). We observed a significant 3-fold increased risk of BC in the first-degree relatives (parent, full sibling, or child of patient) of female HL patients with subsequent BC, compared to FDR in controls (HR = 2.8, 95%CI 1.4-5.6; = 0.005). Female HL patients who had a family history of BC were significantly more likely to develop BC, compared to HL patients with no history of BC among relatives (HR = 3.3, 95%CI 1.6-7.1; = 0.002).
Women with HL and a family history of BC are at even higher than anticipated risk of BC, as are their female relatives. Obtaining a thorough family history for a woman preparing to undergo therapy for HL is important for treatment decisions for HL and maintaining an up to date family history over time is also important for the management of a woman's ongoing cancer risks and her surveillance strategy following survival of HL.
霍奇金淋巴瘤(HL)治疗方法的进展显著提高了儿童和成年患者的生存率;然而,HL幸存者的主要死亡原因是HL治疗后的继发性恶性肿瘤[1,2]。在接受HL治疗的女性中,乳腺癌(BC)是最常见的继发性恶性肿瘤[3]。我们探讨了HL与BC在家族中是否存在关联。
利用犹他州人口数据库和犹他州癌症登记处,我们确定了1966年至2014年在犹他州诊断出的988名HL女性患者,她们在患HL之前无BC病史。我们根据有无BC家族史,研究了HL女性患者患BC的风险是否更高。我们还使用Cox回归方法研究了HL和BC女性患者的女性一级亲属(FDR)中BC的家族复发风险。
在988名女性HL患者中,42名(4.3%)随后被诊断为BC,而在9876名匹配对照中,有280名对照(2.8%)在1966年至2014年期间被诊断为BC(<0.05)。我们观察到,与对照中的FDR相比,后续患BC的女性HL患者的一级亲属(患者的父母、同胞或子女)患BC的风险显著增加了3倍(HR = 2.8,95%CI 1.4 - 5.6; = 0.005)。与亲属中无BC病史的HL患者相比,有BC家族史的女性HL患者患BC的可能性显著更高(HR = 3.3,95%CI 1.6 - 7.1; = 0.002)。
有HL且有BC家族史的女性及其女性亲属患BC的风险甚至高于预期。为准备接受HL治疗的女性获取详尽的家族史对于HL的治疗决策很重要,随着时间推移保持最新的家族史对于管理女性持续的癌症风险及其HL存活后的监测策略也很重要。